Transoral Robotic Surgery for Recurrent Tumors of the Upper Aerodigestive Tract (RECUT): An International Cohort Study.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
06 10 2022
06 10 2022
Historique:
received:
23
02
2022
revised:
04
04
2022
accepted:
30
06
2022
pubmed:
10
8
2022
medline:
13
10
2022
entrez:
9
8
2022
Statut:
ppublish
Résumé
Transoral robotic surgery (TORS) is an emerging minimally invasive surgical treatment for residual, recurrent, and new primary head and neck cancers in previously irradiated fields, with limited evidence for its oncological effectiveness. A retrospective observational cohort study of consecutive cases performed in 16 high-volume international centers before August 2018 was conducted (registered at clinicaltrials.gov [NCT04673929] as the RECUT study). Overall survival (OS), disease-free survival, disease-specific survivals (DSS), and local control (LC) were calculated using Kaplan-Meier estimates, with subgroups compared using log-rank tests and Cox proportional hazards modeling for multivariable analysis. Maximally selected rank statistics determined the cut point for closest surgical resection margin based on LC. Data for 278 eligible patients were analyzed, with median follow-up of 38.5 months. Two-year and 5-year outcomes were 69.0% and 62.2% for LC, 71.8% and 49.8% for OS, 47.2% and 35.7% for disease-free survival, and 78.7% and 59.1% for disease-specific survivals. The most discriminating margin cut point was 1.0 mm; the 2-year LC was 80.9% above and 54.2% below or equal to 1.0 mm. Increasing age, current smoking, primary tumor classification, and narrow surgical margins (≤1.0 mm) were statistically significantly associated with lower OS. Hemorrhage with return to theater was seen in 8.1% (n = 22 of 272), and 30-day mortality was 1.8% (n = 5 of 272). At 1 year, 10.8% (n = 21 of 195) used tracheostomies, 33.8% (n = 66 of 195) used gastrostomies, and 66.3% (n = 53 of 80) had maintained or improved normalcy of diet scores. Data from international centers show TORS to treat head and neck cancers in previously irradiated fields yields favorable outcomes for LC and survival. Where feasible, TORS should be considered the preferred surgical treatment in the salvage setting.
Sections du résumé
BACKGROUND
Transoral robotic surgery (TORS) is an emerging minimally invasive surgical treatment for residual, recurrent, and new primary head and neck cancers in previously irradiated fields, with limited evidence for its oncological effectiveness.
METHODS
A retrospective observational cohort study of consecutive cases performed in 16 high-volume international centers before August 2018 was conducted (registered at clinicaltrials.gov [NCT04673929] as the RECUT study). Overall survival (OS), disease-free survival, disease-specific survivals (DSS), and local control (LC) were calculated using Kaplan-Meier estimates, with subgroups compared using log-rank tests and Cox proportional hazards modeling for multivariable analysis. Maximally selected rank statistics determined the cut point for closest surgical resection margin based on LC.
RESULTS
Data for 278 eligible patients were analyzed, with median follow-up of 38.5 months. Two-year and 5-year outcomes were 69.0% and 62.2% for LC, 71.8% and 49.8% for OS, 47.2% and 35.7% for disease-free survival, and 78.7% and 59.1% for disease-specific survivals. The most discriminating margin cut point was 1.0 mm; the 2-year LC was 80.9% above and 54.2% below or equal to 1.0 mm. Increasing age, current smoking, primary tumor classification, and narrow surgical margins (≤1.0 mm) were statistically significantly associated with lower OS. Hemorrhage with return to theater was seen in 8.1% (n = 22 of 272), and 30-day mortality was 1.8% (n = 5 of 272). At 1 year, 10.8% (n = 21 of 195) used tracheostomies, 33.8% (n = 66 of 195) used gastrostomies, and 66.3% (n = 53 of 80) had maintained or improved normalcy of diet scores.
CONCLUSIONS
Data from international centers show TORS to treat head and neck cancers in previously irradiated fields yields favorable outcomes for LC and survival. Where feasible, TORS should be considered the preferred surgical treatment in the salvage setting.
Identifiants
pubmed: 35944904
pii: 6658385
doi: 10.1093/jnci/djac130
pmc: PMC9552281
doi:
Banques de données
ClinicalTrials.gov
['NCT04673929']
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1400-1409Informations de copyright
© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Head Neck. 2016 Apr;38 Suppl 1:E658-64
pubmed: 25867012
Front Oncol. 2017 Feb 09;7:15
pubmed: 28232904
Head Neck. 2016 Dec;38(12):1855-1861
pubmed: 27405247
Cancer. 1990 Aug 1;66(3):564-9
pubmed: 2364368
Head Neck. 2020 May;42(5):1089-1104
pubmed: 32068940
Curr Opin Oncol. 2007 May;19(3):188-94
pubmed: 17414635
J Laryngol Otol. 2016 May;130(S2):S181-S190
pubmed: 27841130
Clin Adv Hematol Oncol. 2014 Dec;12(12):812-9
pubmed: 25674839
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):731-40
pubmed: 17379449
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
J Clin Oncol. 2014 Oct 20;32(30):3365-73
pubmed: 24958820
Lancet Oncol. 2019 Oct;20(10):1349-1359
pubmed: 31416685
BMC Cancer. 2015 Aug 27;15:602
pubmed: 26311526
Ann Oncol. 2004 Aug;15(8):1179-86
pubmed: 15277256
Front Mol Biosci. 2014 Nov 17;1:24
pubmed: 25988165
Laryngoscope. 2006 Aug;116(8):1465-72
pubmed: 16885755
J Cancer Res Clin Oncol. 2015 Nov;141(11):1985-94
pubmed: 25910988
J Laryngol Otol. 2016 May;130(S2):S13-S22
pubmed: 27841110
Oral Oncol. 2017 Apr;67:1-9
pubmed: 28351561
Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1342-7
pubmed: 19135312
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1067-73
pubmed: 17967302
Ann Oncol. 2020 Nov;31(11):1462-1475
pubmed: 33239190
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):586-594
pubmed: 28865925
JAMA Otolaryngol Head Neck Surg. 2013 Aug 1;139(8):773-8
pubmed: 23949352
Mil Med Res. 2018 Jun 30;5(1):20
pubmed: 29958545